RFA-AG-24-041: Neural and Non-Neural Mechanisms Underlying Gait as a Preclinical Marker for Alzheimers Disease and Alzheimers Disease-Related Dementias (R01 Clinical Trial Optional)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2023.
National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on November 3, 2023.
From the official notice on Grants.gov, last changed August 11, 2023. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR01
- Clinical trialsOptional
- Funded byNIA
- Median yearly award$994,172
- Typical project length5 years
- R01, Research Project Grant. NIH's standard grant for a defined research project led by a named investigator, usually for up to five years. Other open R01 notices.
Projects funded under RFA-AG-24-041 were run by National Institute on Aging (NIA, 4 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-AG-24-041 in the NIH Guide.
Key dates
| Posted | August 11, 2023 |
|---|---|
| Deadline | November 3, 2023 |
| Archived by Grants.gov | December 9, 2023 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Is this a realistic fit?
- Most of the program's money (73% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The purpose of this Notice of Funding Opportunity (NOFO) is to invite applications that investigate the neural and/or non-neural mechanisms that underlie the association between gait and cognition in aging and Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). Elucidating these mechanisms would help inform the potential use of changes gait as an early biomarker of AD/ADRD or inform the design of early interventions for AD/ADRD. To achieve these goals, it will be necessary to facilitate a team science approach by bringing experts together from various relevant disciplines, such as gerontology, neurology, neuropsychology, neurophysiology, neuroscience, neuroimaging, exercise physiology and physical therapy.
Funded under RFA-AG-24-041 so far
NIH funded 4 projects under RFA-AG-24-041 in fiscal 2024 to 2026, at 4 institutions. The median yearly award was $994,172.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Neural mechanisms of gait disturbances as individualized digital biomarker trajectories in preclinical dementia | Stanford University | 2026 | $2.7 million |
| Neural Mechanisms Underlying Cognitive Contributions to Walking as an Early Marker for Risk of Alzheimer’s Disease and Related Dementias | University of Pittsburgh at Pittsburgh | 2026 | $1.0 million |
| Neural Correlates of Cognitive-Motor Interactions in ADRD Gait | University of Florida | 2026 | $801,426 |
| Gait as a Preclinical Marker for Alzheimer’s Disease and Dementia: insights from super-movers, usual-movers, and slow-movers | Albert Einstein College of Medicine | 2024 | $1.2 million |
Who has won Aging Research grants before
From fiscal 2021 to 2025, Aging Research (93.866) awarded $19 billion across 11,026 grant awards, an average of $1.7 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Regents of the University of California, San Francisco | California | 337 | $575 million |
| The Trustees of Columbia University in the City of New York | New York | 242 | $574 million |
| University of Southern California | California | 203 | $572 million |
| The Washington University | Missouri | 210 | $556 million |
| Regents of the University of Michigan | Michigan | 232 | $538 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-AG-24-041 still open?
No. It closed on November 3, 2023.
Who can apply for Neural and Non-Neural Mechanisms Underlying Gait as a Preclinical Marker for Alzheimers Disease and Alzheimers Disease-Related Dementias (R01 Clinical Trial Optional)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Neural and Non-Neural Mechanisms Underlying Gait as a Preclinical Marker for Alzheimers Disease and Alzheimers Disease-Related Dementias (R01 Clinical Trial Optional)?
Closed November 3, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under RFA-AG-24-041?
NIH RePORTER lists 4 projects funded under RFA-AG-24-041 in fiscal 2024 to 2026, at 4 institutions. The most were at Stanford University, University of Pittsburgh at Pittsburgh, University of Florida.
Who has won Aging Research grants before?
The largest recipients over five fiscal years were The Regents of the University of California, San Francisco, The Trustees of Columbia University in the City of New York, University of Southern California. The program made 11,026 awards worth $19 billion in that time.
Similar open grants
- NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required)
- NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required)
- Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)
- Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional)
- Competing Revisions to Existing NIH Single Project Research Grants and Cooperative Agreements (Clinical Trial Optional)
- Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities (R01, Clinical Trial Required)